The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 11, Issue 9, Pages 907-916
Publisher
Informa UK Limited
Online
2016-06-23
DOI
10.1080/17460441.2016.1201057
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic melanoma treatment: Combining old and new therapies
- (2016) Ryan J. Davey et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
- (2015) Paola Queirolo et al. CANCER TREATMENT REVIEWS
- Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
- (2015) Igor Puzanov et al. EUROPEAN JOURNAL OF CANCER
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
- (2015) Giuliana Carlos et al. JAMA Dermatology
- FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
- (2014) G. Kim et al. CLINICAL CANCER RESEARCH
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
- (2014) Antoni Ribas et al. LANCET ONCOLOGY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
- (2012) K. H. T. Paraiso et al. CLINICAL CANCER RESEARCH
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
- (2012) Molly Yancovitz et al. PLoS One
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The MAPK pathway in melanoma
- (2009) Leslie A Fecher et al. CURRENT OPINION IN ONCOLOGY
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
- (2008) E. Sala et al. MOLECULAR CANCER RESEARCH
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search